Advanced search    

Search: authors:"Hans Juergen Grote"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters

. Patterson-Kane. Writing ± review & editing: Manuel A. Silva, Hans Juergen Grote, Janet C. Patterson-Kane. 13 / 15 expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncology 2017; 18:599

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Purpose Agents targeting programmed death receptor 1 (PD-1) or its ligand (PD-L1) have shown antitumor activity in the treatment of metastatic breast cancer (MBC). The aim of this study was to assess the activity of avelumab, a PD-L1 inhibitor, in patients with MBC. Methods In a phase 1 trial (JAVELIN Solid Tumor; NCT01772004), patients with MBC refractory to or progressing after...